Skip to main content
. 2022 Jun 22;10(6):e004381. doi: 10.1136/jitc-2021-004381

Figure 4.

Figure 4

Tumorous miR-21–3p overexpression promotes the therapeutic efficacy of anti-PD-1 antibody by promoting ferroptosis. (A) A schematic view of the treatment plan that C57BL/6 mice burdened with B16F10 tumors with or without tumorous miR-21–3p overexpression received anti-PD-1 antibody and liprostatin-1 treatment as indicated. (B-D) Images of isolated tumors from mice that received indicated treatment. Tumor volumes and weights in each group were calculated and displayed in (C) and (D). (E) Immunofluorescence staining of PTGS2 and TXNRD1 in isolated transplanted tumors with indicated treatment. Scale bar=50 µm. (F) Relative lipid ROS in isolated transplanted tumors with indicated treatment. Data represent the mean±SD of triplicates. P value was calculated by two-tailed Student’s t-test. *P<0.05, **p<0.01, ***p<0.001. ns, non-significant; PD-1, programmed cell death protein 1; ROS, receiver operating characteristic; TXNRD1, thioredoxin reductase 1.